9 completed, 3 recruiting, 3 unknown, 2 terminated. 6 Not applicable, 4 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 3, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Neuroaxonal Dystrophies: new trials by email Literature Review of Neuroaxonal Dystrophies trials Research Report on Neuroaxonal Dystrophies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brain Iron in Beta-Propeller Protein Associated Neurodegeneration (BPAN) Standardized brain MRI including specific sequences usable for Quantitative Susceptibility Mapping (QSM) - Neurodegeneration With Brain Iron Accumulation (NBIA), Iron Metabolism Disorders | Not applicable | Not yet recruiting | University Hospital, Bordeaux | 3 | 2026-12-01 | 2026-10-09 |
| Neurodegenerative Diseases Progression Markers (MARKERS-NDD) Observation - Neurodegenerative Diseases, Parkinson Disease | Recruiting | Casa di Cura San Raffaele Cassino | 600 | 2024-09-09 | 2026-09-02 | |
| Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment. Dematerialized Personalized Care Plan (ePCP) - Sarcoma Metastatic, Locally Advanced Soft Tissue Sarcoma | Not applicable | Recruiting | Centre Oscar Lambret | 377 | 2024-05-29 | 2026-03-18 |
| Functional Tests to Resolve Unsolved Rare Diseases. Rares. Ex-vivo approach concerning 25 patients, In-vitro approach concerning 25 patients - Intellectual Disability, Rubinstein-Taybi Syndrome | Not applicable | Unknown | University Hospital, Bordeaux | 50 | 2023-01-30 | 2024-02-21 |
| European Registry on Rare Neurological Diseases Data set as defined by the ERN Research Workgroup of the European Commission - Rare Diseases | Unknown | University Hospital Tuebingen | 5000 | 2021-10-01 | 2021-09-29 | |
| Occupational Therapy and Cognitive Challenges After Brain Injury The Perceive, Recall, Plan and Perform System of Intervention - Brain Injuries, Cognitive Impairment | Not applicable | Completed | Norwegian University of Science and Technology | 6 | 2021-04-28 | 2024-12-05 |
| CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN) CoA-Z, Placebo - Pantothenate Kinase-Associated Neurodegeneration | Not applicable | Completed | Oregon Health and Science University | 77 | 2019-12-04 | 2025-10-29 |
| A Natural History Study of Infantile Neuroaxonal Dystrophy Neuroaxonal Dystrophy, Infantile | Completed | Biojiva LLC | 43 | 2019-06-17 | 2022-04-08 | |
| Desipramine in Infantile Neuroaxonal Dystrophy (INAD). Desipramine - Infantile Neuroaxonal Dystrophy | Phase 4 | Terminated | Duke University | 4 | 2019-01-14 | 2020-10-14 |
| A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy RT001 - Infantile Neuroaxonal Dystrophy | Phase 2 / Phase 3 | Active not recruiting | Biojiva LLC | 19 | 2018-11-05 | 2021-10-14 |
| Natural History of Infantile Neuroaxonal Dystrophy Infantile Neuroaxonal Dystrophy, INAD | Completed | Biojiva LLC | 13 | 2018-07-30 | 2020-06-29 | |
| Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants. Establishment of mitochondrial markers, Sequencing tests - Neurodegeneration With Brain Iron Accumulation (NBIA) | Completed | University Hospital, Bordeaux | 70 | 2018-01-04 | 2022-11-14 | |
| Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants Fosmetpantotenate, Placebo - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Terminated | Travere Therapeutics, Inc. | 84 | 2017-07-17 | 2021-01-26 |
| NBIAready: Online Collection of Natural History Patient-reported Outcome Measures Neurodegeneration With Brain Iron Accumulation (NBIA) | Unknown | Susan J. Hayflick | 300 | 2015-04-01 | 2020-10-08 | |
| Patient and Provider Initiated Survivorship Care Planning 'My Care Plan', 'Survivorship Care Plan Builder' - Cancer | Not applicable | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 41 | 2015-02-01 | 2016-04-21 |
| Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration Deferiprone oral solution - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 68 | 2014-06-01 | 2020-08-25 |
| Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN) Pantothenate Kinase-associated Neurodegeneration (PKAN) | Completed | Susan J. Hayflick | 10 | 2013-04-01 | 2018-05-29 | |
| Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN) Deferiprone oral solution, Placebo - Pantothenate Kinase-Associated Neurodegeneration | Phase 3 | Completed | ApoPharma | 89 | 2012-12-13 | 2019-07-05 |
| TIRCON International NBIA Registry Neurodegeneration With Brain Iron Accumulation (NBIA), Pantothenate Kinase-associated Neurodegeneration (PKAN) | Recruiting | LMU Klinikum | 2000 | 2012-06-14 | 2025-06-05 | |
| Compassionate Use of Deferiprone in Patients With PKAN Deferiprone - Pantothenate Kinase-Associated Neurodegeneration | No longer available | Chiesi Canada Corp | 2022-11-14 |
Pantothenate Kinase-Associated Neurodegeneration (13) · Cognitive Dysfunction (2) · Albinism (1) · Alzheimer Disease (1) · Amyotrophic Lateral Sclerosis (1) · Ataxia (1) · Brain Diseases (1) · Brain Injuries (1) · Chorea (1) · Corticobasal Degeneration (1) · Cystic Fibrosis (1) · Dementia (1) · Dystonia (1) · Familial apoceruloplasmin deficiency (1)
Central Nervous System Diseases (20) · Nervous System Diseases (20) · Brain Diseases (19) · Basal Ganglia Diseases (13) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (13) · Heredodegenerative Disorders, Nervous System (13) · Movement Disorders (12) · Neurodegenerative Diseases (12) · Mental Disorders (4) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Cognition Disorders (3)
Deferiprone (3) · Isoflurophate (2) · Desipramine (1) · Long Interspersed Nucleotide Elements (1) · Observation (1) · RT001 (1) · fosmetpantotenate (1)
Biojiva LLC (3) · University Hospital, Bordeaux (3) · ApoPharma (2) · Susan J. Hayflick (2) · Casa di Cura San Raffaele Cassino (1) · Centre Oscar Lambret (1) · Chiesi Canada Corp (1) · Duke University (1) · LMU Klinikum (1) · Norwegian University of Science and Technology (1) · Oregon Health and Science University (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Travere Therapeutics, Inc. (1) · University Hospital Tuebingen (1)
United States (10) · France (5) · Italy (5) · Germany (4) · Canada (2) · Czechia (2) · Norway (2) · Poland (2) · Spain (2) · United Kingdom (2) · China (1) · Egypt (1) · India (1) · Netherlands (1) · Saudi Arabia (1)
Peter Milner, MD (3) · Susan J Hayflick, MD (3) · Thomas Klopstock, MD (3) · Elliott Vichinsky, MD (2) · Fernando Tricta, MD (1) · Heidi Vifladt (1) · Katherine C Smith, Ph.D. (1) · Nardo Nardocci, MD (1) · Patrick Chinnery, MD (1) · Penelope Hogarth, M.D. (1) · Thomas Klopstock, Prof. Dr. (1)
PMID 28410187, PMID 31055958, PMID 31202468, PMID 36198473, PMID 37380207, PMID 37605305, PMID 39744963, PMID 41270188
R01HD097328 (1)